

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI

Charmacy Pharmaceutical Co., Ltd.

創美藥業股份有限公司

(A joint stock limited liability company established in the People's Republic of China)
(Stock Code: 2289)

UPDATE ON RESTORATION OF PUBLIC FLOAT

References are made to (i) composite offer and response documents of the Company dated 20 January 2023 (the “**Composite Document**”); (ii) the announcement jointly issued by Jiangyao Group Co., Ltd.* (江藥集團有限公司) (previously known as Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd.* (江西江中醫藥商業運營有限責任公司)) (the “**Jiangyao Group**”), the Offeror and the Company dated 16 February 2023 in respect of, among other things, the results and settlement of the Offer (the “**Results of Offer Announcement**”); (iii) the announcement of the Company dated 1 March 2023 in respect of the granting of waiver (the “**Grant of Waiver Announcement**”); and (iv) the announcement of the Company dated 14 June 2023 in respect of the grant of extension of waiver (the “**Grant of Extension of Waiver Announcement**”). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Composite Document, the Grant of Waiver Announcement and the Grant of Extension of Waiver Announcement.

The Company would like to provide an update on the restoration of public float of the Company.

On 31 August 2023, the Company was informed by the Offeror, the Offeror and a purchaser (the “**Purchaser**”) has entered into a share sales and purchase agreement and executed the bought and sold notes to effect the disposal of an aggregate of 3,656,500 Shares, representing approximately 3.38% of the total number of the issued share capital of the Company, by the Offeror to the Purchaser

(the “**Disposal**”). To the best knowledge and belief of the Company having made all reasonable enquiries, neither the Purchaser nor its ultimate beneficial owner is a core connected person (as defined under the Listing Rules) of the Company and are members of the public within the meaning of Rule 8.24 of the Listing Rules.

Immediately after the completion of the Disposal, a total of 27,000,000 Shares, representing approximately 25.00% of the total number of issued share capital of the Company as at the date of this announcement, will be held by the public. Accordingly, the minimum public float of the Company as required under Rules 8.08(1)(a) and 13.32(1) of the Listing Rules will be restored.

Further announcement will be made upon the completion of the Disposal as and when appropriate.

By Order of the Board
Charmacy Pharmaceutical Co., Ltd.

Yan Jingbin

Chairman

Shantou, the PRC, 31 August 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive directors of the Company are Mr. Yan Jingbin, Ms. Fu Zheng and Mr. Xu Fei; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Li Hanguo and Mr. Guan Jian (also known as Guan Suzhe).

** For identification purposes only*